Biogen Idec Becomes Biogen
- New Corporate Identity and Brand Reflect Company’s Heritage and Commitment to Patients and Science
Biogen Idec was created in 2003 through the merger of Biogen and IDEC Pharmaceuticals, creating one of the world’s leading research-based life sciences organizations. The company has since focused its research and commercial efforts in three core areas: neurology, immunology and hematology.
Biogen’s common stock will continue to trade on the Nasdaq Global Select Market under the symbol “BIIB,” and its CUSIP number will not change.
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.
Website: http://www.biogen.com
Contact
Biogen
MEDIA CONTACT:
Jason Glashow
+1-781-464-3260
public.affairs@biogen.com
INVESTOR CONTACT:
Carlo Tanzi, Ph.D.
+1-781-464-2442
IR@biogen.com
This news is a press release provided by Biogen.
-
2016년 4월 28일 14:00